Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2211523> ?p ?o }
Showing triples 1 to 51 of
51
with 100 triples per page.
- Q2211523 subject Q7469560.
- Q2211523 subject Q8388304.
- Q2211523 subject Q8758634.
- Q2211523 subject Q8918235.
- Q2211523 subject Q9052323.
- Q2211523 abstract "Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.Potential additional uses might be restless legs syndrome (RLS) and epilepsy. They were being tested in Phase II trials in 2008, but no results are available.".
- Q2211523 atcPrefix "none".
- Q2211523 casNumber "133865-89-1".
- Q2211523 casSupplemental "(mesylate)".
- Q2211523 fdaUniiCode "90ENL74SIG".
- Q2211523 iupacName "N2-{4-[(3-fluorobenzyl)oxy]benzyl}-(L)-alaninamide".
- Q2211523 pubchem "131682".
- Q2211523 thumbnail Safinamide.svg?width=300.
- Q2211523 wikiPageWikiLink Q11085.
- Q2211523 wikiPageWikiLink Q12140.
- Q2211523 wikiPageWikiLink Q130146.
- Q2211523 wikiPageWikiLink Q170304.
- Q2211523 wikiPageWikiLink Q181136.
- Q2211523 wikiPageWikiLink Q198473.
- Q2211523 wikiPageWikiLink Q21098885.
- Q2211523 wikiPageWikiLink Q21098995.
- Q2211523 wikiPageWikiLink Q269829.
- Q2211523 wikiPageWikiLink Q2779401.
- Q2211523 wikiPageWikiLink Q410954.
- Q2211523 wikiPageWikiLink Q41571.
- Q2211523 wikiPageWikiLink Q420077.
- Q2211523 wikiPageWikiLink Q421700.
- Q2211523 wikiPageWikiLink Q7180990.
- Q2211523 wikiPageWikiLink Q7469560.
- Q2211523 wikiPageWikiLink Q7553303.
- Q2211523 wikiPageWikiLink Q824258.
- Q2211523 wikiPageWikiLink Q8388304.
- Q2211523 wikiPageWikiLink Q8758634.
- Q2211523 wikiPageWikiLink Q8918235.
- Q2211523 wikiPageWikiLink Q899647.
- Q2211523 wikiPageWikiLink Q903441.
- Q2211523 wikiPageWikiLink Q9052323.
- Q2211523 wikiPageWikiLink Q916280.
- Q2211523 atcPrefix "none".
- Q2211523 casNumber "133865".
- Q2211523 iupacName "N2-{4-[oxy]benzyl}-(L)-alaninamide".
- Q2211523 pubchem "131682".
- Q2211523 unii "90".
- Q2211523 type ChemicalSubstance.
- Q2211523 type Drug.
- Q2211523 type ChemicalObject.
- Q2211523 type Thing.
- Q2211523 type Q8386.
- Q2211523 comment "Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006.".
- Q2211523 label "Safinamide".
- Q2211523 depiction Safinamide.svg.